AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Phospholipase DDHD1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8NEL9

UPID:

DDHD1_HUMAN

Alternative names:

DDHD domain-containing protein 1; Phosphatidic acid-preferring phospholipase A1 homolog; Phospholipid sn-1 acylhydrolase

Alternative UPACC:

Q8NEL9; G5E9D1; Q8WVH3; Q96LL2; Q9C0F8

Background:

Phospholipase DDHD1, also known as Phosphatidic acid-preferring phospholipase A1 homolog, plays a crucial role in lipid metabolism by hydrolyzing glycerophospholipids at the sn-1 position. This enzyme prefers phosphatidate as a substrate but can also act on a variety of other glycerophospholipids, significantly impacting the regulation of polyunsaturated lipids in the nervous system. Its activity influences mitochondrial morphology and the endogenous content of pivotal signaling lipids.

Therapeutic significance:

Given its involvement in lipid metabolism and the nervous system, Phospholipase DDHD1's dysfunction is linked to Spastic paraplegia 28, a neurodegenerative disorder. Understanding the role of Phospholipase DDHD1 could open doors to potential therapeutic strategies for treating this condition and possibly other lipid metabolism-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.